Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F22%3A00555820" target="_blank" >RIV/67985823:_____/22:00555820 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1111/eci.13650" target="_blank" >https://doi.org/10.1111/eci.13650</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/eci.13650" target="_blank" >10.1111/eci.13650</a>
Alternative languages
Result language
angličtina
Original language name
Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives
Original language description
Prevalence of non-alcoholic fatty liver disease (NAFLD) increases in line with obesity and type 2 diabetes, and there is no approved drug therapy. Polyunsaturated fatty acids of n-3 series (omega-3) are known for their hypolipidaemic and anti-inflammatory effects. Existing clinical trials suggest varying effectiveness of triacylglycerol- or ethyl ester-bound omega-3 in the treatment of NAFLD, without affecting advanced stages such as non-alcoholic steatohepatitis. Preclinical studies suggest that the lipid class used to supplement omega-3 may determine the extent and nature of their effects on metabolism. Phospholipids of marine origin represent an alternative source of omega-3. The aim of this review is to summarise the available evidence on the use of omega-3 phospholipids, primarily in obesity-related NAFLD, and to outline perspectives of their use in the prevention/treatment of NAFLD. A PubMed literature search was conducted in May 2021. In total, 1088 articles were identified, but based on selection criteria, 38 original papers were included in the review. Selected articles describing the potential mechanisms of action of omega-3 phospholipids have also been included. Preclinical evidence clearly indicates that omega-3 phospholipids have strong antisteatotic effects in the liver, which are stronger compared to omega-3 administered as triacylglycerols. Multiple mechanisms are likely involved in the overall antisteatotic effects, involving not only the liver but also adipose tissue and the gut. Robust preclinical evidence for strong antisteatotic effects of omega-3 phospholipids in the liver should be confirmed in clinical trials. Further research is needed on the possible effects of omega-3 phospholipids on advanced NAFLD.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
<a href="/en/project/GA17-11027S" target="_blank" >GA17-11027S: Dietary and pharmacological modulation of SCD1 as a tool for studying the link between ectopic lipid storage and insulin sensitivity in obesity</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Clinical Investigation
ISSN
0014-2972
e-ISSN
1365-2362
Volume of the periodical
52
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
19
Pages from-to
e13650
UT code for WoS article
000679928600001
EID of the result in the Scopus database
2-s2.0-85111860948